Please assess the completion status of the following clinical trial:

Trial Title: Co-administration of Iloprost and Eptifibatide in Septic Shock Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult intensive care patients (age ≥18 years) AND~2. Sepsis, defined as suspected or confirmed site of infection or positive blood culture and ≥2 of 4 systemic inflammatory response syndrome (SIRS) criteria fulfilled within the last 24h:~   * Temperature ≤ 36˚ C or ≥ 38˚C~  * Heart rate ≥ 90 beats per minute~  * Mechanical ventilation for acute respiratory process or respiratory rate ≥ 20 breaths per minute or PaCO2 \< 4.2 kPa~  * WBC ≥ 12,000/mm³ OR ≤ 4,000/mm³ OR \> 10% bands AND~3. Septic shock within the last 24h, defined as:~   * Hypotension (MAP \<70 mmHg, Lactate 4 mmol/L) despite ongoing resuscitation with fluids (crystalloids, colloids, blood products) within the last 24h OR~  * ≥30 ml/kg ideal body weight (IBW) fluid (crystalloids, colloids, blood products) given in the last 24h AND~  * Need for vasopressor/inotropic agents (noradrenaline, adrenaline, dopamine) within the last 24h AND~4. Can be randomized into trial and dosed \< 24h after septic shock diagnosis (the time-point for the septic shock diagnosis corresponds to the time-point where the vasopressor/inotropic therapy (3c) is initiated) AND~5. Consent is obtainable~Exclusion Criteria:~1. Patient is pregnant or breast-feeding~2. Patient weights more than 125 kg~3. Patients with known allergy towards any of the investigational products or contraindications which should be excluded according to the investigational product specifications~4. Patients in whom the clinician finds antithrombotic therapy contraindicated - prophylaxis included~5. Patients at increased risk of bleeding:~   * Surgery in the previous 48h and expected surgery within 48 h~  * Epidural or spinal puncture in the previous 12h~  * Platelet count less than 10,000/mm3 in the previous 24h~  * Need of blood products for bleeding in the previous 24h (3 or more RBC/24 h)~  * Treatment with any antithrombotics within 12h (profylaxis excepted)~  * Current intracranial bleeding~  * Traumatic brain or spinal injury within the last month~6. Patients requiring any form of antithrombotics (beyond profylaxis) in therapeutic doses or prothrombotics in any dose, including:~   * Unfractionated heparin within 8h before the infusion (prophylactic heparin up to 15,000 U/day permitted)~  * LMWH within 12h before the infusion (prophylactic doses permitted)~  * Warfarin within 1 day before the infusion~  * Acetylsalicylic acid more than 650 mg/day within 3 days before the study~  * Thrombolytic therapy within 3 days before the study (catheter clearance doses permitted)~  * GPIIb/IIIa receptor inhibitors within 4 days before the study~  * Antithrombin III with dose greater than 10,000 U within 12h before the study~7. Patients with a do-not-resuscitate order (expected not to survive more than few days because of uncorrectable medical or surgical condition other than sepsis)~8. Patient with chronic renal failure requiring dialysis (renal failure without need for dialysis permitted)~9. Patients who have undergone transplantation of bone marrow, liver, pancreas, heart, lung, or bowel (kidney transplant permitted)~10. Patient with known hypercoagulable condition:~    * Activated protein C resistance~   * Hereditary protein C, protein S, or antithrombin III deficiency~   * Anticardiolipin or antiphospholipid antibody~   * Lupus anticoagulant~   * Homocysteinemia~   * Recent or highly suspected pulmonary embolism or deep venous thrombosis (within 3 months)~11. Patients with known congenital hypocoagulable diseases~12. Patient with known primary pulmonary hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Iloprost+eptifibatide (Type: EXPERIMENTAL): Co-administration of 1 ng/kg/min Ilomedin® and 0.5 µg/kg/min Integrilin® as 48h continuous i.v infusions
- Saline (Type: PLACEBO_COMPARATOR): Double dummy 0.9% saline as 48h continuous i.v infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).